Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab US Large-Cap Growth ETF
SCHG
|
+$2.6B |
| 2 |
Abbott
ABT
|
+$1.29B |
| 3 |
Home Depot
HD
|
+$1.03B |
| 4 |
Devon Energy
DVN
|
+$888M |
| 5 |
PepsiCo
PEP
|
+$880M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$1.6B |
| 2 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$1.5B |
| 3 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$1.34B |
| 4 |
Texas Instruments
TXN
|
+$1.32B |
| 5 |
Coterra Energy
CTRA
|
+$789M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.11% |
| 2 | Financials | 10.61% |
| 3 | Healthcare | 10.33% |
| 4 | Miscellaneous | 9.93% |
| 5 | Industrials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3401
DELISTED
KORE Group Holdings
KORE
| $132K | ﹤0.01% |
+14,308
| New | +$131K |
2026 Q2
0 quarters
|
|
3402
Context Therapeutics
CNTX
$27.9M
| $126K | ﹤0.01% |
+227,850
| New | +$462K |
2026 Q2
0 quarters
|
|
3403
Elicio Therapeutics
ELTX
$49.7M
| $124K | ﹤0.01% |
+31,706
| New | +$318K |
2026 Q2
0 quarters
|
|
3404
Artiva Biotherapeutics
ARTV
$339M
| $115K | ﹤0.01% |
+11,896
| New | +$108K |
2026 Q2
0 quarters
|
|
3405
NN Inc
NNBR
$370M
| $102K | ﹤0.01% |
28,401
| – | – |
2022 Q4
14 quarters
|
|
3406
Purple Innovation
PRPL
$8.15M
| $101K | ﹤0.01% |
11,290
-190
| -2% | -$2.33K |
2019 Q4
26 quarters
|
|
3407
The Joint Corp
JYNT
$99.6M
| $100K | ﹤0.01% |
11,384
-19,618
| -63% | -$173K |
2019 Q2
28 quarters
|
|
3408
Cognition Therapeutics
CGTX
$83.4M
| $97.7K | ﹤0.01% |
84,940
| – | – |
2025 Q3
3 quarters
|
|
3409
Microbot Medical
MBOT
$71.9M
| $97.5K | ﹤0.01% |
50,000
| – | – |
2026 Q1
1 quarter
|
|
3410
MediciNova
MNOV
$74.8M
| $94.4K | ﹤0.01% |
71,506
| – | – |
2024 Q2
8 quarters
|
|
3411
Star Holdings Shares of Beneficial Interest
STHO
$100M
| $93K | ﹤0.01% |
10,186
+10
| +0.1% | +$86 |
2026 Q1
1 quarter
|
|
3412
Silvia, Inc. Common Stock
SVIA
$331M
| $92.4K | ﹤0.01% |
60,000
| – | – |
2026 Q1
1 quarter
|
|
3413
OPAL Fuels
OPAL
$52.4M
| $89K | ﹤0.01% |
40,439
+761
| +2% | +$1.67K |
2025 Q2
4 quarters
|
|
3414
Connect Biopharma Holdings
CNTB
$54.8M
| $87.5K | ﹤0.01% |
+36,760
| New | +$89.1K |
2026 Q2
0 quarters
|
|
3415
Genelux
GNLX
$116M
| $75.3K | ﹤0.01% |
25,023
+23
| +0.1% | +$65 |
2025 Q1
5 quarters
|
|
3416
Quantum-Si Incorporated
QSI
$335M
| $74.9K | ﹤0.01% |
84,612
-372,959
| -82% | -$355K |
2021 Q3
19 quarters
|
|
3417
DHI Group
DHX
$221M
| $65.3K | ﹤0.01% |
17,605
| – | – |
2019 Q1
29 quarters
|
|
3418
flyExclusive
FLYX
$70.4M
| $65.1K | ﹤0.01% |
32,539
+19,740
| +154% | +$45.8K |
2025 Q3
3 quarters
|
|
3419
Rent the Runway
RENT
$60.1M
| $64.9K | ﹤0.01% |
+20,609
| New | +$87.3K |
2026 Q2
0 quarters
|
|
3420
Avita Medical
RCEL
$409M
| $64.7K | ﹤0.01% |
15,674
-30,632
| -66% | -$132K |
2021 Q2
20 quarters
|
|
3421
Spero Therapeutics
SPRO
$69.9M
| $63.1K | ﹤0.01% |
28,565
| – | – |
2022 Q4
14 quarters
|
|
3422
Coya Therapeutics
COYA
$116M
| $58.5K | ﹤0.01% |
10,000
| – | – |
2025 Q1
5 quarters
|
|
3423
Shimmick
SHIM
$129M
| $58K | ﹤0.01% |
+12,698
| New | +$56K |
2026 Q2
0 quarters
|
|
3424
Greenland Energy Co
GLND
$110M
| $55K | ﹤0.01% |
+25,000
| New | +$101K |
2026 Q2
0 quarters
|
|
3425
Southland Holdings
SLND
$42.6M
| $47.1K | ﹤0.01% |
70,907
-32,395
| -31% | -$35.5K |
2023 Q2
12 quarters
|
|
Similar funds
Charles Schwab's Q2 2026 Portfolio in Review
As of Q2 2026, Charles Schwab held 3,591 positions worth $751B, up 15% from $654B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab's Q2 2026 filing shows 136 new, 2,145 increased, 1,132 reduced and 153 closed positions. Its largest new stake was Honeywell Aerospace: 2,031,187 shares worth $449M. The largest sale was Qualcomm, an estimated $1.6B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2026 buy was Honeywell Aerospace: 2,031,187 shares worth $449M.
- Charles Schwab added most to Schwab US Large-Cap Growth ETF in Q2 2026, an estimated $2.6B increase.
- Charles Schwab's biggest Q2 2026 reduction was Qualcomm, cutting an estimated $1.6B.
- Charles Schwab fully exited Coterra Energy in Q2 2026, selling an estimated $789M.
- Charles Schwab's ten largest holdings make up 22% of its $751B portfolio in Q2 2026.
- Charles Schwab opened 136 new positions and closed 153 in Q2 2026.
- Charles Schwab's portfolio value rose 15% quarter-over-quarter to $751B.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.